507 related articles for article (PubMed ID: 31243259)
81. Discontinuation of biologic therapy due to lack/loss of response and adverse events is similar between TNFi and non-TNFi class: Results from a real-world rheumatoid arthritis cohort.
Movahedi M; Hepworth E; Mirza R; Cesta A; Larche M; Bombardier C
Semin Arthritis Rheum; 2020 Oct; 50(5):915-922. PubMed ID: 32911288
[TBL] [Abstract][Full Text] [Related]
82. Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis.
Castagné B; Viprey M; Martin J; Schott AM; Cucherat M; Soubrier M
PLoS One; 2019; 14(8):e0220178. PubMed ID: 31369575
[TBL] [Abstract][Full Text] [Related]
83. Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register.
Bechman K; Oke A; Yates M; Norton S; Dennison E; Cope AP; Galloway JB
Rheumatology (Oxford); 2020 Sep; 59(9):2563-2571. PubMed ID: 31998962
[TBL] [Abstract][Full Text] [Related]
84. Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry.
Narongroeknawin P; Chevaisrakul P; Kasitanon N; Kitumnuaypong T; Mahakkanukrauh A; Siripaitoon B; Katchamart W;
Int J Rheum Dis; 2018 Jan; 21(1):170-178. PubMed ID: 28737837
[TBL] [Abstract][Full Text] [Related]
85. Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in Canada.
Movahedi M; Choquette D; Coupal L; Cesta A; Li X; Keystone EC; Bombardier C; Investigators O
BMJ Open; 2023 Mar; 13(3):e063198. PubMed ID: 36878650
[TBL] [Abstract][Full Text] [Related]
86. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
[TBL] [Abstract][Full Text] [Related]
87. Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study.
Barbulescu A; Delcoigne B; Askling J; Frisell T
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32669452
[TBL] [Abstract][Full Text] [Related]
88. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
89. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.
Silva-Fernández L; Lunt M; Kearsley-Fleet L; Watson KD; Dixon WG; Symmons DP; Hyrich KL;
Rheumatology (Oxford); 2016 Nov; 55(11):2033-2039. PubMed ID: 27550304
[TBL] [Abstract][Full Text] [Related]
90. Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry.
Kawabe A; Nakano K; Kubo S; Asakawa T; Tanaka Y
Arthritis Res Ther; 2020 Jun; 22(1):136. PubMed ID: 32513309
[TBL] [Abstract][Full Text] [Related]
91. Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis.
Zhao SS; Yoshida K; Jones GT; Hughes DM; Duffield SJ; Tedeschi SK; Lyu H; Moots RJ; Solomon DH; Goodson NJ
Arthritis Res Ther; 2019 Jul; 21(1):177. PubMed ID: 31331375
[TBL] [Abstract][Full Text] [Related]
92. Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ren S; Bermejo I; Simpson E; Wong R; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Jul; 36(7):769-778. PubMed ID: 29502174
[TBL] [Abstract][Full Text] [Related]
93. Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt.
Romão VC; Santos MJ; Polido-Pereira J; Duarte C; Nero P; Miguel C; Costa JA; Bernardes M; Pimentel-Santos FM; Barcelos F; Costa L; Melo Gomes JA; Pereira da Silva JA; Cunha Branco J; Canas da Silva J; Pereira da Silva JA; Fonseca JE; Canhão H
Biomed Res Int; 2015; 2015():279890. PubMed ID: 26000286
[TBL] [Abstract][Full Text] [Related]
94. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
Finckh A; Ciurea A; Brulhart L; Möller B; Walker UA; Courvoisier D; Kyburz D; Dudler J; Gabay C;
Ann Rheum Dis; 2010 Feb; 69(2):387-93. PubMed ID: 19416802
[TBL] [Abstract][Full Text] [Related]
95. Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data.
Sugiyama N; Kawahito Y; Fujii T; Atsumi T; Murata T; Morishima Y; Fukuma Y
Clin Ther; 2016 Jun; 38(6):1359-1375.e1. PubMed ID: 27101816
[TBL] [Abstract][Full Text] [Related]
96. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
[TBL] [Abstract][Full Text] [Related]
97. Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study.
Gabay C; Riek M; Hetland ML; Hauge EM; Pavelka K; Tomšič M; Canhao H; Chatzidionysiou K; Lukina G; Nordström DC; Lie E; Ancuta I; Hernández MV; van Riel PL; van Vollenhoven R; Kvien TK
Ann Rheum Dis; 2016 Jul; 75(7):1336-42. PubMed ID: 26374404
[TBL] [Abstract][Full Text] [Related]
98. Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice.
Bykerk VP; Östör AJK; Alvaro-Gracia J; Pavelka K; Román Ivorra JA; Nurmohamed MT; Luder Y; Sidiropoulos PNM; Devenport J; Sibilia J
Clin Rheumatol; 2019 Sep; 38(9):2411-2421. PubMed ID: 31028551
[TBL] [Abstract][Full Text] [Related]
99. Effectiveness of biologic and non-biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: New evidence from real-world data.
Paul SK; Montvida O; Best JH; Gale S; Pethoe-Schramm A; Sarsour K
Semin Arthritis Rheum; 2018 Feb; 47(4):478-484. PubMed ID: 28947313
[TBL] [Abstract][Full Text] [Related]
100. Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases.
Pombo-Suárez M; Seoane-Mato D; Díaz-González F; Sánchez-Alonso F; Sánchez-Jareño M; Cea-Calvo L; Castrejón I
Adv Rheumatol; 2023 Jun; 63(1):25. PubMed ID: 37287051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
